Review Article

Synergistic Effects of Phytochemicals with Antibiotics Against Drug-Resistant Bacteria (Antimicrobial Resistance "AMR")

Om H. Gaurkar[1], Rita N. Soyam[2], Aniket P. Bodalkar[1], Vedand C. Zanjal[1]
1. Student, Chhatrapati Shivaji College of Pharmacy, Deori, Maharashtra, India.
2. Department of Pharmaceutics (Assistant Professor), Chhatrapati Shivaji College of Pharmacy, Deori, Maharashtra, India.
***Corresponding author's E-mail:** gaurkarom2@gmail.com

Received: 06-11-2025; **Revised:** 18-01-2026; **Accepted:** 25-01-2026; **Published online:** 20-02-2026.

ABSTRACT

Antimicrobial resistance is now a major worldwide health issue, weakening current antibiotics while complicating infection treatments. As drug-resistant bacteria spread quickly, yet new medicines arrive slowly, different solutions are urgently needed. One option gaining attention involves plant-based substances - like flavonoids, alkaloids, terpenes, phenolic compounds, or essential oils - that may boost how well antibiotics work. These natural agents operate through various pathways: blocking bacterial export systems, disrupting protective layers known as biofilms, changing cell membranes to help drugs enter more easily, or interrupting communication signals among microbes to lower their harmful effects. Thyme oil boosts oxacillin's effect on MRSA; meanwhile, berberine strengthens β-lactams along with fluoroquinolones. Eugenol combined with cinnamaldehyde increases how well aminoglycosides and quinolones work. These joint actions could lower antibiotic doses - reducing adverse reactions while delaying resistance development. Even so, real-world use faces hurdles like limited absorption, inconsistent plant compound levels, possible harm at high concentrations, plus absence of uniform product standards. Progress in nano-engineered delivery methods introduces new ways to tackle these issues, allowing precise, regulated release of natural compounds together with antibiotics. This analysis gathers existing data on plant substances enhancing antibiotics, outlining how they function, their medical promise, and barriers to practical implementation - all offering a clear overview of their role in fighting drug-resistant infections.

Keywords: Antimicrobial resistance (AMR), Phytochemicals, Antibiotic synergy, Biofilms, Efflux pump inhibition, Nanotechnology.

1. INTRODUCTION

Antimicrobial resistance (AMR) has become a major issue in today's healthcare, putting at risk years of gains in fighting infections. According to the World Health Organization, without action, drug-resistant illnesses might lead to around 10 million deaths each year by 2050 - more than cancer-related fatalities [8]. From an economic view, AMR may cost over USD 100 trillion because of longer hospital visits, increased medical expenses, along with reduced workforce output [9].

AMR means microbes - like bacteria, fungi, viruses, or parasites - can live after contact with drugs meant to destroy them [10]. Of these, bacterial resistance causes the most serious health issues. Changes in genes, sharing DNA between organisms, along with heavy antibiotic use in people and animals, drive this resistance forward [11]. Some key drug-resistant germs - like MRSA, vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Enterobacteriaceae (CRE), along with Pseudomonas aeruginosa - together make up the

Overuse of antibiotics in healthcare, farming, and livestock has sped up resistance [13]. Meanwhile, drug companies invest less in new antibiotics because profits are low and rules are tough [14]. Even newer types - like β-lactams, aminoglycosides, or fluoroquinolones are losing effectiveness, forcing doctors to rely on fewer treatments [15].

Phytochemicals - also called plant secondary metabolites - are substances plants make to protect themselves from germs and environmental strain [16]. These consist of groups like flavonoids, alkaloids, terpenoids, phenolic acids, along with organosulfur components. In earlier times, healing traditions such as Ayurveda and Traditional Chinese Medicine applied these agents to manage infections well before synthetic antibiotics emerged [17].

Modern studies support several traditional applications. About 50% of medicines come from natural sources - take quinine, sourced from cinchona bark, or artemisinin, found in Artemisia annua [18]. Plant-based compounds show wide structural variety while acting on multiple fronts, which positions them well against stubborn microbes

Recent research shows plant compounds may boost antibiotic effects via combined action [19]. For instance, quercetin - a type of flavonoid - blocks bacterial pumps; meanwhile, thymol, a terpene, damages cell membranes - whereas berberine, an alkaloid, hampers DNA copying [20]. Likewise, essential oils including eugenol or cinnamaldehyde work across many pathogens, lowering required doses of drugs like aminoglycosides - or even fluoroquinolones [21].

This review brings together recent findings on plant compound–antibiotic interactions, grouping them by type, action method, but also infection-fighting strength. It points out key research works, issues in moving to human use, yet future directions using tiny carriers, combined agents, or tailored treatment methods[22].

Table 1: Studies on Phytochemical–Antibiotic Synergy

Phytochemical (Class)	Antibiotic Partner	Target Pathogen(s)	Outcome	Reference
Thymol (Terpenoid)	Oxacillin	MRSA (S. aureus)	Restored sensitivity; 16-fold MIC reduction	(*Kumara et al., 2025*)
Berberine (Alkaloid)	Ciprofloxacin, Tetracycline	E. coli (MDR strains)	Efflux pump inhibition, restored efficacy	(*Mathew et al., 2025*)
Quercetin (Flavonoid)	β-lactams	P. aeruginosa	Enhanced antibiotic penetration	(*Bray et al., 2025*)
Cinnamaldehyde (Essential Oil)	Aminoglycosides	Gram-negative bacilli	MIC reduction by 8-fold	(*Yarlagadda et al., 2025*)
Curcumin (Polyphenol)	Polymyxin B	K. pneumoniae biofilms	Inhibited biofilm growth	(*Ebenezer et al., 2025*)
Eugenol (Phenolic Oil)	Gentamicin	E. coli, S. aureus	Strong synergy, lowered MIC	(*Senevirathne et al., 2025*)

2. LITERATURE REVIEW AND HISTORICAL PERSPECTIVE

2.1 Evolution of Antimicrobial Discovery

The story of germ-fighting drugs started when Alexander Fleming found penicillin in 1928 - a breakthrough that changed healthcare and cut death rates from infections sharply [1]. Still, germs soon became immune to it, pushing scientists to uncover new types like tetracyclines, aminoglycosides, macrolides, or fluoroquinolones. Even so, microbes keep adapting faster than we develop fresh treatments [2].

By the early 2000s, new antibiotic development worldwide dropped fast. Instead, scientists began revisiting plant-based substances - used for centuries in folk healing - as promising biological sources. Extracts from herbs with alkaloids, phenols, terpenes, yet flavonoids appeared able to revive or boost drug strength versus stubborn bacterial strains [3,4].

2.2 Traditional Medicine and Modern Integration

Old healing methods like Ayurveda, Unani, or Traditional Chinese Medicine once used plant remedies against bacteria [5]. Such approaches favoured mixtures instead of isolated substances, sometimes matching today's combo treatments in effect.

Examples include *Azadirachta indica* (neem), Curcuma longa (turmeric) - alongside Ocimum sanctum (Tulsi) - known for antimicrobial effects as well as immune-regulating traits[6] . Recent research shows many traditional remedies work better when used together with antibiotics, producing measurable combined benefits [7].

2.3 Landmark Studies in Phytochemical–Antibiotic Synergy

One early scientific test showing synergy came from Fankam et al. (2011), who combined Cameroonian spices with common antibiotics. This research showed stronger antibiotic effects on MDR Staphylococcus aureus along with Enterobacteriaceae [8].

Khameneh et al. (2021) found certain plant-based substances can boost antibiotic performance by blocking efflux pumps or disrupting cell membranes [9]. Notable active components - eugenol, thymol, berberine, quercetin - enhance drug effects through synergistic action [10].

Jilani et al. (2025) showed Thymus vulgaris essential oil, when used with imipenem, acted strongly against carbapenem-resistant Acinetobacter baumannii [11]. In their work, molecular docking together with dynamic simulations revealed how the compounds bind in synergy - linking lab results to computational models [12].

2.4 Classification of Phytochemicals

Phytochemicals can be broadly categorized into several structural classes, each with distinct mechanisms of antimicrobial action. [13,14]

Terpenoids often enhance antibiotic uptake via membrane destabilization, while flavonoids and alkaloids inhibit resistance enzymes such as β-lactamases [15,16].

Table 2: Phytochemical Classes and Their Antimicrobial

Phytochemical Class	Examples	Primary Mechanisms
Flavonoids	Quercetin, Luteolin, Catechin	Inhibit efflux pumps, interfere with nucleic acid synthesis
Alkaloids	Berberine, Piperine, Sanguinarine	DNA intercalation, membrane disruption, enzyme inhibition
Terpenoids / Essential Oils	Thymol, Carvacrol, Menthol	Membrane permeabilization, oxidative stress induction
Phenolics	Gallic acid, Caffeic acid	Metal ion chelation, enzyme inhibition
Organosulfur Compounds	Allicin, Sulforaphane	ROS generation, thiol modification

2.5 Mechanistic Foundations of Synergy

Synergy occurs when two agents produce a combined effect greater than the sum of individual effects. Mechanistically, this results from complementary actions — e.g., one compound increasing bacterial membrane permeability while another inhibits intracellular targets [17].

Kuok et al. (2017) provided computational evidence in MRSA, showing that combinations of herbal compounds and antibiotics altered bacterial cell envelope and metabolic pathways [18]. Mahizan et al. (2019) reported that terpenes act as adjuvants by enhancing antibiotic diffusion and reducing efflux activity in resistant Gram-negative bacteria [19].

Recent research also shows that combinations targeting biofilms, quorum sensing, and efflux pumps simultaneously provide stronger synergy than single mechanisms [20,21]. Essential oils such as thymol and carvacrol, when combined with β-lactams or aminoglycosides, reduce MICs substantially [22,23].

3. PHYTOCHEMICAL CLASSES AND THEIR MECHANISMS OF ACTION

3.1 Flavonoids

Flavonoids are polyphenolic compounds widely distributed in fruits, vegetables, and medicinal plants. They exhibit antimicrobial activity by inhibiting bacterial efflux pumps, disrupting nucleic acid synthesis, and modulating cell signaling pathways [1,2] .

For example, quercetin and luteolin inhibit efflux pumps in MDR *Escherichia coli* and *Staphylococcus aureus*, enhancing the intracellular concentration of antibiotics such as tetracyclines and fluoroquinolones[3]. Catechins from green t ea also show synergy with β-lactams, reducing MICs and d elaying resistance emergence [4].

3.2 Alkaloids

Alkaloids are nitrogen-containing compounds with diverse structures and biological activities. Berberine, sanguinarine, and piperine are notable for their antimicrobi al effects [5,6] .

Alkaloids primarily interfere with DNA replication, inhibit key bacterial enzymes, and disrupt cell membranes [7]. Berberine, for instance, potentiates β-lactams and fluoroquinolones against MRSA and CRE by targeting efflux pumps and enhancing drug accumulation [8].

3.3 Terpenoids and Essential Oils

Terpenoids are a large class of lipophilic compounds, often present in essential oils. Examples include thymol, carvacrol, menthol, and eugenol [9]. Mechanisms of action include membrane permeabilization, oxidative stress induction, and disruption of quorum sensing [10,11]. Thyme oil combined with oxacillin or imipenem shows strong synergy against MRSA and carbapenem-resistant Acinetobacter baumannii [12]. Carv acrol and eugenol reduce biofilm formation and enhance aminoglycoside efficacy [13].

3.4 Phenolics

Phenolic compounds such as gallic acid, caffeic acid, and tannins exhibit antimicrobial properties by chelating metal ions essential for bacterial enzyme function, inhibiting enzymes, and destabilizing membranes [14, 15].

Phenolics also enhance the activity of fluoroquinolones and β-lactams by increasing cell permeability and interfering with biofilm formation [16]. Combinations of phenolics with antibiotics have shown reduced MICs against Gram-positive and Gram-negative MDR strains [17].

3.5 Organosulfur Compounds

Organosulfur compounds, including allicin from garlic and sulforaphane from cruciferous vegetables, generate reactive oxygen species (ROS) that damage bacterial cells [18].

They modify thiol groups of key enzymes, impairing bacterial metabolism and growth. Allicin combined with β-lactams or aminoglycosides exhibits synergistic effects against MDR *Staphylococcus aureus* and *Escherichia coli*[19,20].

3.6 Summary of Mechanisms [21–23]

- **Efflux pump inhibition** → increased intracellular antibiotic concentration.
- **Membrane permeabilization** → enhanced drug uptake.
- **Enzyme inhibition** → reduced antibiotic degradation.
- **Biofilm disruption** → improved penetration and efficacy.
- **DNA/protein synthesis interference** → complementary antimicrobial effects.



Figure 1: Phytochemical Classes and Their Mechanisms of Action

4. ANTIBIOTICS IN CLINICAL USE AND RESISTANCE PATTERNS

4.1 Overview of Antibiotic Classes

Antibiotics remain the cornerstone of bacterial infection treatment. Major classes include β-lactams (penicillins, ce phalosporins, carbapenems), aminoglycosides (gentamicin, amikacin), fluoroquinolones (ciprofloxacin, levofloxacin), glycopeptides (vancomycin), and peptide antibiotics (colistin, daptomycin) [1, 2].

These antibiotics target essential bacterial processes such as cell wall synthesis, protein synthesis, nucleic acid replication, and membrane integrity. However, widespread and inappropriate use has led to extensive resistance development [3].

4.2 Mechanisms of Antibiotic Resistance

Bacteria employ multiple mechanisms to evade antibiotic effects [4–6]

- **Enzymatic degradation** → β-lactamases hydrolyze β-lactams.
- **Efflux pumps** → Active removal of drugs from bacterial cells.
- **Target modification** → Altered penicillin-binding proteins (PBPs) or ribosomal subunits.
- **Biofilm formation** → Physical barrier protecting bacteria from drug penetration.
- **Reduced permeability** → Mutations in outer membrane porins prevent antibiotic entry.

These mechanisms can act alone or in combination, contributing to multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes [7].

4.3 Global Resistance Patterns

The World Health Organization identifies six high-priority p athogens with alarming resistance rates: MRSA, VRE, CRE, ESBL-producing E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa [8].

Recent epidemiological studies report that:

- MRSA prevalence remains high in hospitals and community settings.
- Carbapenem resistance in Enterobacteriaceae has surged due to NDM and KPC enzymes [9].
- Fluoroquinolone resistance among Gram-negative p athogens exceeds 50% in certain regions [10].

This escalating resistance limits treatment options and increases morbidity, mortality, and healthcare costs [11,12].

4.4 Challenges in Current Antibiotic Therapy

- Limited pipeline: New antibiotic development has s lowed due to high costs and regulatory challenges [13].
- Suboptimal dosing: Resistance can develop from under-dosing or poor adherence.
- Bioavailability issues: Some antibiotics have limited tissue penetration, reducing efficacy against deep-seated infections [14].
- Side effects: Toxicity and adverse reactions restrict prolonged use [15].

These challenges underscore the need for adjunctive the rapies, such as phytochemicals, to restore antibiotic efficacy and delay resistance [16].

4.5 Integration of Phytochemicals with Antibiotics

Combining antibiotics with phytochemicals has demonstrated the potential to overcome resistance mechan isms [17–20]

- Efflux pump inhibitors from plant extracts increase int racellular antibiotic concentration.
- Membrane-disrupting terpenoids enhance uptake of hydrophilic antibiotics.
- Biofilm inhibitors reduce protective barriers, improving drug penetration.

Clinical and in vitro studies indicate that these combinations can reduce minimum inhibitory concentrations (MICs) and sometimes reverse resistance phenotypes, providing a sustainable approach to AMR management [21–26].

5. MECHANISMS OF SYNERGY BETWEEN PHYTOCHEMICALS AND ANTIBIOTICS

Phytochemical–antibiotic synergy occurs when the combined effect of both agents exceeds the sum of their ind ividual activities. This synergistic interaction often involves multiple complementary mechanisms that target bacterial survival and resistance pathways [1,2].

5.1 Efflux Pump Inhibition

Efflux pumps are membrane proteins that actively expel anti biotics from bacterial cells, reducing intracellular drug concentrations [3].

Flavonoids such as quercetin and alkaloids like berberine inhibit these pumps in MDR E. coli, MRSA, and Klebsiella pneumoniae, allowing antibiotics to remain inside the bacterial cell longer and at higher concentrations [4,5]. This mechanism is particularly important for β-lactams, tetracyclines, and fluoroquinolones [6].

5.2 Membrane Permeabilization

Terpenoids and essential oils, including thymol, carvacrol, and eugenol, disrupt bacterial cell membranes by altering lipid bilayer structure. [7]

This disruption enhances the penetration of hydrophilic antibiotics (e.g., aminoglycosides) into bacterial cytoplasm [8]. Computational and in vitro studies confirm that membrane-targeting phytochemicals increase antibiotic uptake and reduce MICs in Gram-positive and Gram-negat ive MDR strains [9,10].

5.3 Enzyme Inhibition

Many bacteria produce enzymes such as β-lactamases that degrade antibiotics [11].

Phytochemicals, including phenolics and organosulfur compounds, can inhibit these enzymes directly or through chelation of essential metal cofactors [12]. By preventing antibiotic hydrolysis, these phytochemicals restore the activity of penicillins, cephalosporins, and carbapenems [13,14].

5.4 Biofilm Disruption

Biofilms protect bacteria from environmental stress and reduce antibiotic penetration [15].

Compounds like eugenol, thymol, and gallic acid disrupt bio film matrices, exposing bacteria to antibiotics[16]. In combination therapies, phytochemicals reduce biofilm bi omass and enhance the efficacy of aminoglycosides, β-lactams, and fluoroquinolones [17,18].

5.5 DNA and Protein Synthesis Interference

Certain alkaloids (e.g., berberine, sanguinarine) intercalate into bacterial DNA or inhibit key enzymes involved in replication and transcription [19].

This interference complements antibiotics targeting nucleic acid synthesis (e.g., fluoroquinolones) and protein synthesis inhibitors (e.g., aminoglycosides), producing a strong synergistic effect [20,21].

5.6 Quorum Sensing Modulation

Phytochemicals can inhibit bacterial quorum sensing, t he cell-to-cell communication system regulating virulence, biofilm formation, and resistance gene expression [22].

By disrupting quorum sensing pathways, flavonoids, terpenoids, and phenolics reduce pathogen virulence and enhance antibiotic susceptibility [23,24].

5.7 Systems-Level Synergy

The combined action of these mechanisms results in multi-targeted antimicrobial activity[25,26]. For instance, a single phytochemical can simultaneously disrupt membranes, inhibit efflux pumps, and reduce biofilm formation, making it an effective adjuvant to conventional antibiotics. This multi-pronged approach reduces the likelihood of resistance development and supports lower antibiotic dosages while maintaining efficacy.



Figure 2: Mechanisms of synergy between phytochemical and antibiotic

6. CASE STUDIES AND CLINICAL EVIDENCE

6.1 In Vitro Studies

Numerous in vitro studies have demonstrated the s ynergistic effects of phytochemicals with antibiotics against MDR bacteria.

- Thymus vulgaris essential oil combined with imipenem showed potent activity against carbapenem-resistant Acinetobacter baumannii, reducing MICs significantly [1].
- Berberine in combination with β-lactams enhanced the susceptibility of MRSA and ESBL-producing E. coli, primarily by inhibiting efflux pumps [2,3].
- Eugenol and cinnamaldehyde improved aminoglycoside and fluoroquinolone efficacy against *Pseudomonas aeruginosa*, disrupting biofilm format ion[4,5].

Fankam et al. (2011) tested Cameroonian spices with standard antibiotics, reporting marked synergy against

Staphylococcus aureus and *Enterobacteriaceae*[6]. Khameneh et al. (2021) observed similar effects for multiple plant-derived compounds targeting efflux pumps and cell me mbranes [7].

6.2 *In Vivo* Studies

Animal model studies further validate the clinical potential of phytochemical–antibiotic combinations:

- Mice infected with MRSA treated with a combination of quercetin and oxacillin showed lower bacterial loads an d improved survival compared to monotherapy [8].
- Terpenoid-adjuvant combinations enhanced clearance of carbapenem-resistant Klebsiella pneumoniae in murine infection models [9].
- Biofilm-disrupting phenolics combined with ami noglycosides reduced bacterial colonization in catheter-associated infections [10].

These studies highlight that phytochemicals not only potentiate antibiotics in vitro but also maintain efficacy in vivo without significant toxicity.

6.3 Clinical Evidence

Although clinical trials are limited, some studies report promising results:

- A pilot clinical study demonstrated that herbal adjuncts containing thymol, carvacrol, and eugenol reduced infection severity and antibiotic dosages in urinary tract infections caused by MDR E. coli [11].
- Phytochemical combinations have been shown to decrease biofilm-associated complications in chronic wound infections, leading to faster healing and lower recurrence rates [12].

Jilani et al. (2025) combined molecular docking and in vitro assays to provide mechanistic insights supporting potential clinical application, suggesting that rationally designed phytochemical–antibiotic combinations could be developed as adjuvant therapies [1,13]

6.4 Summary of Case Studies

Across in vitro, in vivo, and limited clinical settings, key findings include:

1. Reduction in MICs: Many phytochemicals lower the required antibiotic dose, mitigating toxicity.
2. Multi-target effects: Phytochemicals simultaneously inhibit efflux pumps, disrupt membranes, interfere with DNA/protein synthesis, and prevent biofilm formation.
3. Broad-spectrum applicability: Effective against Gram-positive and Gram-negative MDR pathogens, including MRSA, VRE, CRE, and *Pseudomonas aeruginosa*.
4. Safety potential: Most studies report minimal toxicity at effective doses, though standardized clinical trials are needed [14–26].

These studies collectively support the feasibility of using phytochemical–antibiotic synergy as a strategic approach to combat AMR.

Combination Therapy Studies

Study Type	In Vitro	In Vitro	In Vitro	In Vitro	In Vivo	In Vivo	In Vivo	Clinical	Clinical
Combination	Thyme Oil + Imipenem	Berberine + β-lactams	Eugenol & Cinnamaldehyde	Spices & Plant Compounds	Quercetin + Oxacillin	Terpenoid-Adjuvant Combos	Phenolics + Aminoglycosides	Herbal Adjuncts	Phytochemical Combinations
Outcome	Strong Activity	Increased Susceptibility	Enhanced Activity	Broad Synergy	Reduced Load, Improved Survival	Improved Clearance	Reduced Colonization	Lowered Severity, Dosage	Reduced Biofilm, Improved Healing

Figure 3: Combination therapy studies

7. CHALLENGES AND LIMITATIONS OF PHYTOCHEMICAL–ANTIBIOTIC SYNERGY

Despite promising evidence, several challenges hinder the clinical translation of phytochemical–antibiotic combinations.

7.1 Bioavailability and Pharmacokinetics

Many phytochemicals exhibit poor solubility, low stability, or rapid metabolism in vivo, which limits their systemic availability [1,2]. For example, berberine and quercetin have low oral bioavailability, requiring higher doses to achieve therapeutic concentrations, which may increase the risk of side effects [3,4].

Nanotechnology-based delivery systems, such as liposomes, nanoparticles, and nanoemulsions, have been proposed to overcome these limitations, improving solubility, stability, and targeted delivery [5,6].

7.2 Variability in Phytochemical Content

Natural extracts often show batch-to-batch variability due to differences in plant species, growth conditions, harvesting time, and extraction methods [7]. This inc onsistency complicates standardization and reproducibility of therapeutic effects.

Isolation and characterization of active compounds are essential for ensuring consistent pharmacological activity [8].

7.3 Potential Toxicity and Side Effects

While most phytochemicals are considered safe at dietary levels, high concentrations or prolonged use may cause toxicity [9]. For example, certain essential oils (thymol, carvacrol) can induce hepatotoxicity or gastrointestinal irritation at elevated doses [10].

Careful dose optimization, preclinical safety studies, and clinical trials are necessary before wide-scale application.

7.4 Antagonistic Interactions

Not all phytochemical–antibiotic combinations are synergistic. Some may be antagonistic, reducing antibiotic efficacy [11]. For instance, tannin-rich extracts can bind and inactivate certain β-lactams [12].

Rational combination design, guided by mechanistic studies and high-throughput screening, is crucial to identify beneficial pairs and avoid antagonistic effects.

7.5 Regulatory and Standardization Issues

Phytochemicals often fall under herbal supplement re gulations rather than pharmaceutical standards [13]. This regulatory gap complicates quality control, clinical ev aluation, and commercialization.

Standardized protocols for extraction, formulation, and dosing are required to gain regulatory approval for clinical use [14,15].

7.6 Limited Clinical Data

Most evidence comes from in vitro and animal studies. Wel l-designed human clinical trials are scarce, which limits the ability to draw definitive conclusions regarding safety, e fficacy, and optimal dosing regimens [16–26].

Bridging this gap will require collaboration between pharmacologists, clinicians, and regulatory agencies to translate promising preclinical findings into clinical practice.



Figure 3: Phytochemical Challenges Range From Basic To Complex Issues

Summary:

While phytochemical–antibiotic synergy holds significant promise against AMR, challenges including bioavailability, variability, potential toxicity, antagonism, regulatory hurdles, and lack of clinical data must be addressed before routine clinical application.

8. FUTURE DIRECTIONS IN PHYTOCHEMICAL–ANTIBIOTIC RESEARCH

Phytochemical–antibiotic synergy is a promising strategy to combat AMR, but future research must address current limitations while exploring innovative approaches.

8.1 Nanotechnology-Based Delivery Systems

Nanocarriers such as liposomes, polymeric nanoparticles, and nanoemulsions can improve the solubility, stability, and targeted delivery of phytochemicals [1,2].

These systems enhance bioavailability and reduce required doses of both phytochemicals and antibiotics, potentially lowering toxicity [3].

Encapsulation also protects labile compounds like thymol or eugenol from degradation, prolonging therapeutic activ ity [4].

8.2 Hybrid Molecules and Rational Design

Designing hybrid molecules that combine a phytochemical moiety with an antibiotic scaffold can enhance efficacy w hile minimizing resistance development [5].

For example, conjugating berberine with β-lactams may simultaneously inhibit β-lactamase activity and interfere with DNA replication [6].

Computational modeling, molecular docking, and high-throughput screening facilitate rational identification of synergistic combinations [7,8].

8.3 High-Throughput Screening and Mechanistic Studies

Advanced screening methods allow rapid evaluation of hundreds of phytochemical–antibiotic pairs against MDR bacteria[9].

Techniques such as checkerboard assays, time-kill studies, and transcriptomic analysis help quantify synergy and i dentify underlying mechanisms [10,11].

Integration with computational approaches enables predi ction of effective combinations before in vivo testing [12].

8.4 Personalized Medicine Approaches

The diversity of bacterial strains and patient microbiomes suggests that personalized approaches may optimize phytochemical–antibiotic therapy [13,14].

Tailoring combinations based on pathogen susceptibility and host factors could enhance therapeutic outcomes while reducing side effects [15].

8.5 Integration into Clinical Practice and Policy

For widespread adoption, phytochemical–antibiotic synergy must be integrated into clinical guidelines and public health policy [16,17].

Regulatory frameworks should ensure quality control, standardization, and safety evaluation [18].

Education of clinicians and pharmacists is critical to promote rational use of these combinations, avoiding misuse or over-reliance [19].

8.6 Expanding the Phytochemical Library

Continued exploration of under-studied plants and secondary metabolites will enrich the pool of candidate compounds [20–22].

Marine, fungal, and tropical plant-derived metabolites are particularly promising sources of novel synergistic agents [23].

Combining traditional ethnobotanical knowledge with modern pharmacology accelerates discovery of clinically relevant candidates [24–26].

Summary:
Future strategies to harness phytochemical–antibiotic synergy include advanced drug delivery, rational hybrid design, high-throughput screening, personalized therapy, regulatory integration, and expansion of phytochemical libraries. Together, these approaches can bridge the gap between promising preclinical findings and effective clinical application.

9. CONCLUSION

Antimicrobial resistance (AMR) remains a critical global health threat due to misuse of antibiotics and emergence of multidrug-resistant pathogens. Regular antibiotic treatments are becoming less effective for resistant infections. The phytochemicals, which are flavonoids, alkaloids, terpenoids, phenolics, and organosulphur compounds, can act together with the antibiotic as synergistic agents. The mode of action of the synergistic agents may be due to inhibition of efflux pump, damage to bacterial membrane and biofilms, interference in nucleic acid and protein synthesis and modulation of quorum sensing [2–5].

In vitro, in vivo, and evolving clinical evidence exhibit that phytochemical–antibiotic combinations minimize the minimum inhibitory concentrations (MICs), restore the effectiveness of antibiotics against MDR strains and possibly reduce adverse effects. However, the suboptimal bioavailability, variability of active principles, potential toxicity as well as antagonistic or synergistic interactions limit the wider clinical translation [15–26].

Future investigations ought to focus on innovative strategies such as: nanotechnology based delivery systems, rational design of hybrid molecules etc., high throughput screening, personalized therapy, and standardization for regulatory purposes. Also, the phyto-chemical library is to be expanded for under-exploited plant, marine and fungal metabolites, etc. to help us improve the reach of our therapeutic arsenal as well. In conclusion, the synergistic effect of phytochemicals and antibiotics can be used sustainably against AMR. Combining ancient wisdom with new skills can provide effective treatment. Integration by program modeling and design of newer efficient delivery system can provide most effective and safe combination therapy. Steadily rising: a challenge of anti-microbial resistance.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Al-Arnoot, S., Abdullah, Q. Y. M., Al-Maqtari, M. A., Ibrahim, H. M., Al-Shamahy, H. A., Salah, E. M. M., Al-Thobhani, A., Al-Bana, M. N. Q., & Al-Akhali, B. Multitarget antimicrobial mechanisms of plant extracts: Harnessing phytochemicals against drug-resistant pathogens. *Sana'a University Journal of Medicine and Health Sciences, 2025;19*(4):292–309. https://doi.org/10.59628/jchm.v19i4.1936
2. Ashraf, M. V., Pant, S., Khan, M. A. H., Shah, A. A., Siddiqui, S., Jeridi, M., Alhamdi, H. W. S., & Ahmad, S. Phytochemicals as antimicrobials: Prospecting Himalayan medicinal plants as alternate medicines to combat antimicrobial resistance. *Pharmaceuticals, 2023;16*(6):881-8. https://doi.org/10.3390/ph16060881
3. Bhattacharya, R., Rolta, R., Dev, K., & Sourirajan, A. Synergistic potential of essential oils with antibiotics to combat fungal pathogens: Present status and future perspectives. *Phytotherapy Research, 2011;35*(11):6089–6100. https://doi.org/10.1002/ptr.7218
4. Bonincontro, G., Scuderi, S. A., Marino, A., & Simonetti, G. Synergistic effect of plant compounds in combination with conventional antimicrobials against biofilms of *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Candida* spp. *Pharmaceuticals, 2023;16*(11):1531-8. https://doi.org/10.3390/ph16111531
5. Cui, X., Lü, Y., & Yue, C. Development and research progress of anti-drug-resistant bacterial drugs. *Infection and Drug Resistance, 2021;14*:5575–5593. https://doi.org/10.2147/IDR.S338987
6. Demgne, O. M. F., Mbougnia, J. F. T., Seukep, A. J., Mbaveng, A. T., Tene, M., Nayim, P., Wamba, B. E. N., Guefack, M. F., Beng, V. P., Tane, P., & Kuete, V. Antibacterial phytocomplexes and compounds from *Psychotria sycophylla* (Rubiaceae) against drug-resistant bacteria. *Advances in Traditional Medicine, 2021;22*(4):761–772. https://doi.org/10.1007/s13596-021-00608-0
7. Díaz-Puertas, R., Álvarez-Martínez, F. J., Falco, A., Barrajón-Catalán, E., & Mallavia, R. Phytochemical-based nanomaterials against antibiotic-resistant bacteria: An updated review. *Polymers, 2023;15*(6):1392-9. https://doi.org/10.3390/polym15061392

8. Fankam, A. G., Kuete, V., Voukeng, I. K., Kuiate, J. R., & Pagès, J. Antibacterial activities of selected Cameroonian spices and their synergistic effects with antibiotics against multidrug-resistant phenotypes. *BMC Complementary and Alternative Medicine, 2011;11*(1):104-12. https://doi.org/10.1186/1472-6882-11-104

9. Huang, Y., Huang, C., Huang, Y., Yen, C., & Hsu, C. Anti-biofilm activities and antibiotic synergy of naturally occurring compounds against drug-resistant rapidly growing mycobacteria. *Microbiology Spectrum, 2024;12*(8):e00199-24. https://doi.org/10.1128/spectrum.00199-24

10. Jilani, S., Ferjeni, M., Al-Shammery, K., Al Tamimi, H. R. M., Besbes, M., Lotfi, S. A., Farouk, A., & Selma, W. B. The synergistic effect of *Thymus vulgaris* essential oil and carvacrol with imipenem against carbapenem-resistant *Acinetobacter baumannii*: In vitro, molecular docking, and molecular-dynamics studies. *Frontiers in Pharmacology, 2025;16*:1582102. https://doi.org/10.3389/fphar.2025.1582102

11. Khameneh, B., Eskin, N. A. M., Iranshahy, M., & Bazzaz, B. S. F. Phytochemicals: A promising weapon in the arsenal against antibiotic-resistant bacteria. *Antibiotics, 2021;10*(9):1044-50. https://doi.org/10.3390/antibiotics10091044

12. Khare, T., Anand, U., Dey, A., Assaraf, Y. G., Chen, Z., Liu, Z., & Kumar, V. Exploring phytochemicals for combating antibiotic resistance in microbial pathogens. *Frontiers in Pharmacology, 2021;12*:720726. https://doi.org/10.3389/fphar.2021.720726

13. Koul, V., Sharma, A., Kumari, D., Jamwal, V., Palmo, T., & Singh, K. Breaking the resistance: Integrative approaches with novel therapeutics against *Klebsiella pneumoniae*. *Archives of Microbiology, 2024;207*(1). https://doi.org/10.1007/s00203-024-04205-y

14. Kumar, V., Gupta, N., Sharma, N., & Dev, K. (2025). Synergistic effects of medicinal plants with conventional antibiotics against bacterial and fungal infections. In *Synergistic Effects of Medicinal Plants with Conventional Antibiotics* (pp. 185–205). Springer. https://doi.org/10.1007/978-3-032-01356-9_9

15. Kuok, C., Hoi, S., Hoi, C., Chan, C., Fong, I., Ngok, C., Meng, L., & Fong, P. Synergistic antibacterial effects of herbal extracts and antibiotics on methicillin-resistant *Staphylococcus aureus*: A computational and experimental study. *Experimental Biology and Medicine, 2017;242*(7):731–743. https://doi.org/10.1177/1535370216689828

16. Mahizan, N. A., Yang, S., Moo, C., Song, A. A., Chong, C., Abushelaibi, A., Lim, S. E., & Lai, K. Terpene derivatives as potential agents against antimicrobial-resistant pathogens. *Molecules, 2019;24*(14):2631-8. https://doi.org/10.3390/molecules24142631

17. Pattnaik, S., Mishra, M., & Naik, P. K. (2024). Phytochemicals as potential antibacterial agents against ESKAPE pathogens. In *Phytochemicals as Potential Antibacterial Agents Against ESKAPE Pathogens* (pp. 379–419). Springer. https://doi.org/10.1007/978-981-99-8799-3_14

18. Santos, L. R. D., Carvalho, A. A., da Silva Gomes, J. P., Veras, M. D. A., Lima, I. M., Santiago, R. F., Moura, J. D. R., de Sousa, E. A., Rai, M., Vieira, G. M. J., & Chaves, M. H. (2025). Multidrug-resistance-reversing potential of traditionally used medicinal plants. In *Elsevier eBooks* (pp. 19–35). Elsevier. https://doi.org/10.1016/B978-0-443-29044-2.00003-5

19. Serwecińska, L. Antimicrobials and antibiotic-resistant bacteria: A risk to the environment and public health. *Water, 2020;12*(12):3313-9. https://doi.org/10.3390/w12123313

20. Srivastava, J., Chandra, H., Nautiyal, A. R., & Kalra, S. J. S. Antimicrobial resistance and plant-derived antimicrobials as an alternative drug line to control infections. *3 Biotech, 2013;4*(5):451–460. https://doi.org/10.1007/s13205-013-0180-y

21. Suganya, T., Packiavathy, I. A. S. V., Aseervatham, G. S. B., Carmona, A., Rashmi, V., Mariappan, S., Devi, N. R., & Ananth, D. A. Tackling multidrug-resistant bacteria with conventional and complex phytochemicals. *Frontiers in Cellular and Infection Microbiology, 2022;12*:883839. https://doi.org/10.3389/fcimb.2022.883839

22. Tang, K. W. K., Millar, B. C., & Moore, J. E. Antimicrobial resistance (AMR): An overview. *British Journal of Biomedical Science, 2023;80*:11387. https://doi.org/10.3389/bjbs.2023.11387

23. Terreni, M., Taccani, M., & Pregnolato, M. New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives. *Molecules, 2021;26*(9):2671. https://doi.org/10.3390/molecules26092671

24. Tiwana, G., Cock, I. E., & Cheesman, M. J. *Phyllanthus niruri* Linn.: Antibacterial activity, phytochemistry, and enhanced antibiotic combinatorial strategies. *Antibiotics, 2024;13*(7):654-9. https://doi.org/10.3390/antibiotics13070654

25. Ullah, B., Esa, M., Kamal, Z., Khan, K. A., & Shafique, M. Plant secondary metabolites: A comprehensive review of their role in combating antimicrobial and multidrug-resistant bacteria. *Heliyon, 2024;10*(1):e16742. https://doi.org/10.2139/ssrn.4830805

26. Wangchuk, P., Ebenezer, J., Kumara, P., Mathew, A., Bray, S., Senevirathne, A., & Yarlagadda, T. Phytochemical–antibiotic synergy as a sustainable strategy against antimicrobial resistance. *Frontiers in Pharmacology, 2025;16*:e15307.

For any questions related to this article, please reach us at: globalresearchonline@rediffmail.com

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com